Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer

Stephen Ross,* Gabrielle Agin-Liebes, Sharon Lo, Richard J. Zeifman, Leila Ghazal, Julia Benville, Silvia Franco Corso, Christian Bjerre Real, Jeffrey Guss, Anthony Bossis, and Sarah E. Mennenga

ABSTRACT: People with advanced cancer are at heightened risk of desire for hastened death (DHD), suicidal ideation (SI), and completed suicide. Loss of Meaning (LoM), a component of demoralization, can be elevated by a cancer diagnosis and predicts DHD and SI in this population. We completed a randomized controlled trial in which psilocybin-assisted psychotherapy (PAP) produced rapid and sustained improvements in depression, demoralization, and hopelessness in people with cancer. Converging epidemiologic and clinical trial findings suggests a potential antisuicidal effect of this treatment. To probe our hypothesis that PAP relieves SI through its beneficial impacts on depression and demoralization (LoM in particular), we performed secondary analyses assessing within- and between-group differences with regard to LoM and an SI composite score. Among participants with elevated SI at baseline, PAP was associated with within-group reductions in SI that were apparent as early as 8 h and persisted for 6.5 months postdosing. PAP also produced large reductions in LoM from baseline that were apparent 2 weeks after treatment and remained significant and robust at the 6.5 month and 3.2 and 4.5 year follow-ups. Exploratory analyses support our hypothesis and suggest that PAP may be an effective antisuicidal intervention following a cancer diagnosis due to its positive impact on hopelessness and demoralization and its effects on meaning-making in particular. These preliminary results implicate psilocybin treatment as a potentially effective alternative to existing antidepressant medications in patients with cancer that are also suicidal, and warrant further investigation in participants with elevated levels of depression and suicidality.

KEYWORDS: psilocybin, psychedelic, cancer, depression, suicidal ideation, demoralization, loss of meaning

INTRODUCTION

There are approximately 48 000 and 804 000 deaths by suicide each year in the United States1 and worldwide,2 respectively, making suicide a leading cause of death. A diagnosis of cancer is a known risk factor for increased suicidal ideation (SI) and behavior and studies of completed suicide in cancer patients have reported prevalence rates up to 4 times greater than that in the general population.3–10 A systematic review and meta-analysis (k = 22 studies) of cancer diagnosis and suicide mortality reported a pooled standardized mortality ratio (SMR) of 1.55 (95% CI = 1.37–1.74).10 However, a retrospective, population-based study of a nationally representative sample including 8 651 569 patients with cancer reported a SMR = 4.44, indicating that risk of completed suicide might increase 4-fold following a cancer diagnosis.9 The association between cancer and increased suicide risk is predominantly mediated by advanced illness (i.e., poor prognosis and disease progression), uncontrolled pain, psychiatric distress (major depression in particular), and existential distress (hopelessness and helplessness).11–18 Importantly, within the context of cancer-related psychiatric and existential distress, there is little evidence for current pharmacologic interventions effectively targeting SI [for a review, see ref 19]. There is, therefore, a need for exploring innovative treatment strategies for reducing SI among individuals with life-threatening cancer, especially interventions that can work rapidly.

A more subtle manifestation of SI in patients with advanced cancer is the desire for hastened death (DHD), that is, the
wish for a more rapid death than would naturally occur. DHD has been reported in 9–22% of patients with advanced or terminal cancer, is more common in palliative care settings,6,20–24 and has similarly been shown to be associated with physical distress, low social support, depression, demoralization, hopelessness, and lack of spiritual well-being.35,36 Among these, depression and hopelessness appear to predominantly mediate DHD in advanced cancer,24,27–31 and improving spiritual well-being in advanced cancer is associated with decreased hopelessness, depression, and desired for hastened death.32 In a study of HIV/AIDS patients, a population with similar rates of existential distress,33 DHD was significantly elevated among patients with past histories of suicide attempts,34 suggesting a bridge between DHD and SI. Demoralization syndrome, a manifestation of existential distress in patients with advanced cancer, consists of hopelessness and helplessness caused by lack of purpose and meaning related to confronting death, and occurs in up to one-third of patients with advanced cancer.35 Loss of meaning (LoM) associated with demoralization syndrome has been shown to be positively correlated with DHD.36

Psilocybin-Assisted Psychotherapy for Cancer-Related Anxiety, Depression, and Existential Distress. Among the numerous clinical indications for which treatment with classic hallucinogens, such as psilocybin, have been investigated, psychiatric and existential disorders related to life-threatening cancer emerge as front-runners in terms of the published evidence from modern RCTs.37,38 Two recently published review articles39,40 identified several published clinical trials in which subjects with advanced- or terminal-cancer-related psychiatric and existential distress were treated with a serotonergic psychedelic (i.e., psilocybin, LSD, and dipropyltryptamine (DPT)), including four open-label trials of LSD therapy (N = 244) published between 1964 and 198041–44 and four RCTs (N = 104) published between 2011 and 2016.45–48 The historical open-label trials suggested that LSD-assisted psychotherapy was associated with rapid analgesic effects that endured for several weeks, improvements in psychiatric distress (depression, anxiety, insomnia) and existential distress (death anxiety), and improved psychiatric outcomes associated with mystical experiences.41–43 Three RCTs completed within the past decade (UCLA-Harbor, NYU Langone Health (NYULH)/Bellevue Hospital, and Johns Hopkins) assessed the efficacy of single-dose psilocybin-assisted psychotherapy in patients with advanced-cancer-related psychiatric and existential distress (N = 92).45,47–49 Results from these trials indicate that a single moderate to high dose of psilocybin, delivered in conjunction with psychotherapy, produces rapid, substantial (i.e., large effect sizes and high rates of psychiatric illness remission), and sustained (i.e., months to years) reductions in anxiety and depressive symptoms, as well as sustained reductions in existential distress, and improved quality-of-life. In addition, psilocybin occasioned mystical-type experiences, experienced as highly meaningful and spiritual, partially mediated anxiolytic and antidepressant effects assessed longitudinally (i.e., 5–7 weeks) postadministration of psilocybin.45,47–50

Psilocybin-Assisted Psychotherapy for Cancer-Related SI: Converging evidence. There is indirect evidence from epidemiologic studies that psilocybin may also have antisuicidal effects. Population-level analysis of data from the National Survey on Drug Use and Health found that lifetime classic psychedelic use was associated with 14% reduced likelihood of past-year suicidal thinking, 29% reduced likelihood of past year suicidal planning, and 36% reduced likelihood of past year suicide attempts.50 An epidemiologic study of marginalized women (i.e., street-involved sex workers, unhoused, and drug users) in Canada found that lifetime psychedelic use was associated with a 60% reduced suicidality hazard (adjusted hazard ratio: 0.40; 95% CI 0.17–0.94).51 An open-label trial in which individuals with treatment-resistant major depressive disorder received two doses of psilocybin along with supportive psychotherapy reported decreases in SI up to 2 weeks after the intervention.52 Additional evidence from an open-label53 and a RCT54 suggest that single-dose ayahuasca administration is associated with rapid (i.e., within 40 min) and sustained (i.e., 1–3 weeks) decreases in suicidality in patients with major depressive disorder. Interestingly, among the classic psychedelics, psilocybin in particular may be protective against SI and behaviors.55

The NYULH/Bellevue Hospital trial and its ancillary long-term follow-up study did not explore suicidality as primary or secondary outcomes, and excluded participants with active SI or suicidal behaviors at screening. However, findings indicate that psilocybin-assisted psychotherapy improves several constructs related to SI and DHD, including depression, cancer-related hopelessness and demoralization, and spiritual well-being.47,49 Meaning-making was a key existentially oriented component of the psychotherapeutic platform within which psilocybin treatment was delivered,47 and several themes have emerged from qualitative analyses that implicate LoM specifically as a likely symptom of demoralization syndrome that psilocybin-assisted psychotherapy might target reduction of SI.56 Suicidality and symptoms of depression often change independently of one another,57 and not all interventions for depression are effective for relieving suicidality. For instance, SSRIs, a first-line intervention for depression, show limited efficacy for suicidality in particular,58 and may even increase suicidality within certain populations.59 Thus, determining whether and how psilocybin-assisted psychotherapy reduces SI in addition to its established antidepressive effects in people with cancer has emerged as an important question.

Rationale for Present Analyses. To assess whether a single dose of psilocybin, administered in conjunction with psychotherapy, produces acute and sustained antisuicidal effects in patients with advanced cancer, we performed post hoc analyses of relevant data from our completed NYULH/Bellevue Hospital trial.47 Our aims were to (1) determine whether single-dose psilocybin-assisted psychotherapy acutely relieves SI and LoM; (2) evaluate the longevity of reductions in SI and LoM; and (3) examine relationships between SI, other (non-SI-related) depressive symptoms, and potential mediators of psilocybin’s antisuicidal effects, including demoralization, hopelessness, and spiritual well-being within people that have been given a cancer diagnoses. We hypothesized that psilocybin treatment would be associated with significant acute and sustained reductions in SI and LoM and that reductions in SI would be positively associated with improvements in other depressive symptoms, LoM, demoralization, hopelessness, and spiritual well-being.

METHODS

Study Design and Interventions. Our previously completed double-blind, randomized, crossover, controlled trial was designed to assess the efficacy of a single, moderate-to-high dose of oral psilocybin per session (0.3 mg/kg) versus
a single-dose session of an orally administered active control (niacin 250 mg). Both treatment conditions were administered in conjunction with dyadic psychotherapy to treat clinically significant anxiety and/or depression as well as existential distress in patients with life-threatening cancer [see ref 47 for more details]. A subsample of participants from the parent trial participated in two additional long-term follow-up assessments that occurred on average at 3.2 years (range = 2.3–4.5 years) and 4.5 years (range = 3.5–5.5 years) following the participants’ psilocybin dosing date.49 The parent trial and long-term follow-up were approved by the NYULH Perlmutter Cancer Protocol Review and Monitoring Committee and the Institutional Review Board (IRB) of the New York University (NYU) School of Medicine (SOM). Figure 1 presents an overview of the relevant aspects of the parent trial and ancillary follow-up study.

**Sample.** Major qualifying criteria for the parent trial include a DSM-IV Axis I Disorders-Patient Version diagnosis of adjustment disorder with anxiety ± depression, acute stress disorder, generalized anxiety disorder (GAD), or anxiety disorder due to cancer; a projected life expectancy of at least 1 year; and no psychiatric risk factors such as family history of schizophrenia. Of 108 prescreened participants, 42 provided informed consent, 31 were randomized into the experimental or control group, 29 received study medication, and 11 were included in this secondary analysis due to detectable baseline levels of SI (see Figure 2 for the CONSORT flow diagram).

**Assessments.** Suicidal Ideation (SI). As our primary outcome, we created a composite score representing SI from scores on two items from the Beck Depression Inventory-II (BDI-II) and the Brief Symptom Inventory (BSI). Item 9 on the BSI (“thoughts of ending your life”) and item 9 on the BDI, which queries SI with response options of “I do not have any thoughts of killing myself” (0), “I have thoughts of killing myself, but I would not carry them out” (1), “I would like to kill myself” (2), and “I would kill myself if I had the chance” (3). There is ample precedent for calculating a composite SI score using all available items (or measures) that examine the effects of a pharmacological agent on suicidality, both in clinical trials that have included stand-alone SI measures and those that have not.62–66 Price et al.64 used a similar methodology including items from the BSI and the Montgomery–Asberg Depression Rating Scale (MADRS), and Ballard et al.63 used items from the BDI and Hamilton Depression Rating Scale (HAM-D) to create composite SI scores. Because the BDI-II and BSI utilize disparate Likert scales, we computed Z-scores for each item, summed them, and transformed the summed Z-scores into standardized T-scores with a range of 0–100,67 with higher scores indicating a higher SI. SI was assessed at baseline, 8 h after dose 1, 2 weeks after dose 1, 7 weeks after dose 1 (corresponding to 1 day prior to dose 2), and 6.5 months after dose 2. Because only the BDI-II was administered at the 3.2 and 4.5 year assessments, a composite SI score was not generated at these time points. The Supporting Information shows the relationship between responses to the two items that contributed to the SI composite score.

**Loss of Meaning (LoM).** The Demoralization Scale (DS), a 24 item questionnaire with Likert scale response categories ranging from 0 to 4 developed to measure existential distress in advanced cancer, has shown good reliability (Cronbach’s α ranging from 0.71 to 0.89) and concurrent validity with related scales.60 The scale generates five factors: LoM, despair, disheartened feelings, helpless feelings, and sense of failure. Because the LoM factor from the DS has been shown to positively correlate with scores on a validated measure of DHD (the Schedule of Attitudes toward Hastened Death, SAHD; $r = 0.67$),36 we chose scores on this factor as our secondary
outcome. Scores on the following five items from the Demoralization Scale contributed to LoM factor scores: “Life is no longer worth living”, “I would rather not be alive”, “My life seems to be pointless”, “I would rather not go on living”, and “There is no purpose to the activities in my life”. LoM was assessed at baseline, 2 weeks post dose 1, 6.5 months post dose 2, and at the 3.2 and 4.5 year assessments.

**Other Depressive Symptoms.** The remaining items from the BDI-II (SI items removed) were scored to represent other (non-SI) depressive symptoms. The BDI-II is a self-report measure of depression comprising 21 questions related to depressive symptoms experienced over the previous 2 weeks rated on a 3-point scale (total score ranges from 0 to 63). Scores greater than 12 indicate evidence of clinical depression. This measure demonstrates good reliability (internal consistency 0.90) and factorial validity.68 Change in other depressive symptoms was assessed from baseline to 2 weeks after dose 1.

**Hopelessness.** The Hopelessness Assessment in Illness (HAI) is an 8 item existential distress scale that assesses hopelessness in advanced cancer. Total scores range from 0 to 16, with higher scores indicating greater levels of hopelessness. This measure has shown adequate internal consistency (Cronbach’s α = 0.87) and concurrent validity (r = 0.70–0.78).69 The HAI was assessed at baseline, 2 weeks post dose 1, 6.5 months post dose 2, and at the 3.2 and 4.5 year follow-up assessments.

**Spiritual Well-Being.** The Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being (FACIT-Sp-12)70 is a 12 item measure of spiritual well-being in patients with cancer and other forms of chronic illness. The items are rated on a five-point Likert scale yielding three subscales: a sense of meaning, inner peace and purpose in life; a sense of comfort and strength derived from one’s faith; and a total spiritual well-being score. The FACIT-Sp-12 shows strong internal consistency (Cronbach’s α ranging from 0.81 to 0.88) and is a well-validated scale.70 The FACIT-Sp-12 was assessed at baseline, 2 weeks post dose 1, 6.5 months post dose 2, and at the 3.2 and 4.5 year follow-up assessments.

**Statistical Analysis.** Data were combined from the original parent investigation47 and the ancillary long-term follow-up study49 for posthoc analyses. Participants who met criteria for having a baseline level of suicidality (defined as a composite SI score > 0 on BDI item 9 + BSI item 9) were included; this approach was chosen to mitigate floor effects and optimally address the current aims. We performed post hoc power analyses to determine how much power we had to detect small, medium, and large effect sizes with the sample size and measures available to us from the parent trial. Results indicated that analyses of outcomes with four repeated measures were sufficiently powered (>0.80) to detect large effect sizes (f > 0.4), and analyses with two repeated measures were only sufficiently powered to detect very large effect sizes (f > 0.5).

Mixed effect models with repeated measures (MMRMs) were constructed in SPSS (version 25) using an AR(1) covariance structure for each outcome of interest.
covariance structure and fixed effects of group and time. Several planned within-group (change from baseline) and between-group (psilocybin-first vs niacin-first) comparisons of interest were specified a priori to assess the impact of psilocybin treatment on SI and LoM (Tukey’s posthoc). Scores on SI and LoM within each treatment group were compared at each available follow-up assessment, and scores at each available follow-up assessment time point were contrasted with baseline scores within each treatment group. After the crossover, both the psilocybin-first and niacin-first dose-sequence groups were collapsed and combined into one group. This approach was fchosen to increase power given the modest sample size, since the crossover design prevented further meaningful between-group comparisons. The long-term effects of psilocybin on SI and LoM were assessed within the MMRM framework using planned within-subject comparisons assessing change from baseline to each available postcrossover follow-up time point. Effect sizes were tentatively estimated as Cohen’s d, although deviations from normality and small sample size were expected to introduce bias into these estimates.

Finally, we assessed correlations between composite SI scores and LoM scores, and between change in SI from baseline to 2 weeks after dose 1 and change in other depressive symptoms, demoralization (DS), hopelessness (HAI), and spiritual well-being (FACIT-Sp-12) from baseline to 2 weeks after dose 1.

### RESULTS

#### Demographics

Demographic information for the subsample of participants included in the current analyses is presented in Table 1. The mean age of participants was 60.3 years old (standard deviation (SD) = 7.1 years), and they were predominately female (63.6%). The majority of participants were non-Hispanic White (90.9%), followed by Multiracial (9.1%). Approximately 46% of participants identified as Atheist/Agnostic versus some other organized religious affiliation. Gynecological cancers (54.6%) comprised most disease types. Nearly three-quarters of participants (72.8%) were diagnosed with advanced [III–IV] versus early [I–II] stage (27.2%) cancers. Approximately one-third (36.4%) of all participants reported one or more occasions of prior psychedelic use. The majority of participants met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for cancer-related adjustment disorder with anxious and depressed features (45.5%) or adjustment disorder with anxious (only) features (45.5%), followed by generalized anxiety disorder (9.1%). Compared to the parent study sample, the proportions of current study participants were roughly equivalent in all demographic variables and did not statistically differ, nor did the two dose-sequence groups.

**Acute Effects of Psilocybin-Assisted Psychotherapy on SI and LoM.** Within the psilocybin-first group, significant main effects of time were detected in analyses of SI \( F_{(4,23)} = 9.55, p < 0.001 \) and LoM \( F_{(4,18)} = 5.60, p = 0.004 \). Within-group comparisons specified a priori indicated that scores on SI and LoM differed significantly at all post dose 1 administration session time points relative to baseline (LoM: 2 weeks post dose 1, \( p = 0.005 \); SI: 8 h post dose 1, \( p < 0.001 \); 2 weeks, post dose 1 \( p < 0.001 \); and 7 weeks post dose 1, \( p < 0.001 \)). Prior to the crossover in the niacin-first group, the effect of time approached, but did not reach significance for SI \( F_{(4,19)} = 2.64, p = 0.065 \) or LoM \( F_{(4,10)} = 9.64, p = 0.079 \). We did not detect a main effect of group on SI \( (p = 0.614) \), and the interaction between group and time approached, but did not reach significance \( (p = 0.065; Figure 3a) \). LoM analyses revealed a main effect of group \( F_{(1,11)} = 6.49, p = 0.027 \) with no interaction between group and time \( F_{(4,27)} = 0.67, p = 0.429 \; \text{Figure 3a} \). Pairwise comparisons specified a priori indicated that mean scores on LoM differed substantially between the psilocybin-first and niacin-first groups at 2 weeks after dose 1 \( (p = 0.021) \). Effect sizes across statistically significant comparisons were large (Cohen’s d = 1.20–3.50).

**Long-Term Effects of Psilocybin-Assisted Psychotherapy on SI and LoM.** After the crossover, within-subjects reductions, relative to baseline, remained significant at the 6.5 month follow-up for SI \( (p < 0.001) \) and LoM \( (p < 0.001; \text{Figure 3b}) \). Reductions in LoM continued to be significant at the 3.2 year \( (p < 0.001) \) and 4.5 year \( (p < 0.001) \) follow-ups. Effect sizes for significant effects were again large (Cohen’s d = 1.51−2.56).

**Relationships between SI, LoM, and Other Depressive Symptoms.** There was a moderate positive correlation between LoM scores and SI scores collapsed across all assessment time points \( r = 0.41, p = 0.02; \text{Figure 4a} \). Reductions from baseline to 2 weeks post dose 1 in SI were positively and strongly correlated with reductions from baseline to 2 weeks post dose 1 in other depressive symptoms \( r = 0.75, p = 0.008; \text{Figure 4b} \). Correlations between reductions in SI and hopelessness and demoralization were large, offering support to our hypothesis even though they did not reach significance with the current (underpowered) approach \( \text{HAi: } r = 0.62, p = 0.059; \text{DS: } r = 0.57, p = 0.067 \), but the correlation between reductions in spiritual well-being (FACIT-Sp-12) did not approach significance \( (r = 0.015, p = 0.966) \).
antidepressant medications are only very modestly effective at reducing suicidality, and might actually increase suicidality. The current results are consistent with epidemiological data suggesting that psilocybin use is associated with antisuicidal effects and with an open-label study of oral psilocybin treatment in patients with treatment-resistant depression. The risks of psilocybin-assisted psychotherapy have been described in detail within the primary publication, but are expected to be minimal as long as it is delivered in carefully controlled clinical settings.

Clinical Implications in Psychiatry and Psycho-Oncology. If psilocybin’s antisuicidal effects are confirmed in people with higher baseline SI levels, then it could represent a novel, and much-needed, avenue for treatment of major depressive disorder (MDD) in people that are suicidal. There are some biological interventions within psychiatry that have an evidence base for reducing SI, including electroconvulsive therapy (ECT), clozapine, lithium, and ketamine, although all present significant limitations. ECT takes 1–2 weeks for SI to be reduced, and transient and sometimes enduring cognitive side effects have been documented. Lithium has been shown to reduce suicide risk in patients with bipolar disorder in the long term, although it has not been shown to work acutely. Furthermore, lithium’s narrow therapeutic index requires close monitoring to prevent toxicity and risk of death. Clozapine has been shown to have antisuicidal effects in schizophrenia spectrum disorders and some evidence for efficacy in bipolar disorder, although it carries a significant and potentially fatal side effect profile and has not been shown to decrease SI in the acute setting either.

It especially makes sense to study psilocybin as a novel treatment for depression and suicidality in MDD given recent findings of ketamine treatment in this population. Despite differing primary receptor mechanisms of action, ketamine (a N-methyl-D-aspartate receptor antagonist and dissociative anesthetic) and psilocybin (a serotonin-2a receptor agonist and serotonergic hallucinogen) possess similarities in terms of modulating glutamatergic transmission and functional connectivity in prefrontal-limbic circuits, subjective effects (i.e., mystical-type experiences), and neuroplastic potential (i.e., increased brain-derived neurotrophic factor (BDNF) expression and increased synaptic plasticity). This is relevant given that ketamine, the first pharmacologic agent shown to possess rapid and short-term (e.g., up to 1–2 weeks) improvements in depressive symptoms, has been shown to rapidly (i.e., within 1 day) reduce suicidal thoughts for up to 1 week in patients with MDD and SI. If psilocybin were found to also have rapid, as well as sustained, antisuicidal effects (i.e., weeks to months to years) after a single-dose, then it would be of considerable clinical benefit for suicide prevention in mood disorders therapeutics.

Given the limited evidence that pharmacologic interventions effectively target SI among individuals with cancer, if the above findings can be replicated in future trials, then it could represent a potentially novel paradigm in psychiatry and psycho-oncology in terms of a single dose of a medication leading to rapid or acute reductions in suicidality with enduring (i.e., months to years) and clinically meaningful effects. Given the major risk factors for suicide in cancer (i.e., male, middle age, advanced cancer illness, clinically significant depression, hopelessness, and pain), psilocybin-assisted psychotherapy could target patients with advanced or terminal forms of cancer who are experiencing elevated rates of
depression, existential distress, or pain, and associated DHD, SI, and suicidal behaviors. The therapy could be applied in inpatient or outpatient settings and could be especially helpful to patients at the end-of-life in hospice settings. More broadly, psilocybin could be used at any stage of cancer, including early diagnosis or chronic forms of cancer where there are relevant target risk factors such as depression, pain, and existential distress. Such preventive interventions could potentially serve to alter or arrest the process by which LoM and DHD could lead to more overt SI and suicidal behaviors. It is also possible that psilocybin-assisted psychotherapy may have efficacy in treating suicidal ideation in life-threatening medical conditions beyond cancer, with associated depression and existential distress.

Putative Mechanisms of the Antisuicidal Effects of Psilocybin Treatment. Our findings are consistent with prior research suggesting central roles for depression and demoralization (i.e., LoM, hopelessness) in mediating DHD and SI in advanced cancer.21,27−31 If psilocybin-assisted psychotherapy is found to produce acute/rapid and long-term sustained reductions in suicidality in cancer patients, then it would be important to explore how this happens, keeping in mind the main drivers of DHD and SI in cancer patients: depression, demoralization, hopelessness, and chronic pain. A conceptual model of causality, supported by evidence in published literature, could be broken down into neurobiological and psycho-spiritual pathways leading to persisting effects and change mechanisms, further narrowing to final common change mechanisms, and ultimately reduction of DHD and SI as the primary outcome measures; large sample size (e.g., N = 100 or more) to provide sufficient power for mediation analysis of target psychological change mechanisms in accounting for improvement in long-term clinical outcomes; inclusion of measures to assess for the various psychological change mechanisms (i.e., mystical experience, cognitive flexibility, structural personality assessment, challenging experiences, and emotional breakthrough); inclusion of a sufficient sample with cancer pain to examine pain as a causal mechanism; and inclusion of techniques to assess potential neurobiological mechanisms of action (i.e., neuroimaging to assess sustained changes in brain network connectivity, neuro-inflammatory biomarkers such as tumor necrosis factor α (TNF-α), and neuroplasticity biomarkers such as BDNF.

Limitations. The primary limitation of our approach is that the parent trial was not designed to assess the antisuicidal effects of psilocybin in patients with advanced cancer. The trial specifically excluded more serious forms of suicidality and did not specifically target patients with suicidality. Because of this, our analyses were substantially underpowered to detect small-to-moderate effect sizes, but they were sufficiently powered to detect the substantial differences reported here. The crossover design of the parent trial limits our ability to assess long-term clinical benefits relative to a control condition, and the relatively homogeneous sample (e.g., 64% female, 91% Caucasian) diminishes the generalizability of the current findings. While post hoc construction of a composite score for SI has sufficient precedent, inclusion of a dedicated measure to assess SI would clearly benefit interpretability of future trials assessing it. Other statistical approaches may also offer additional clarity to the current results, such as those that take the ordinal structure of the response items for the BDI-II and BSI into account.

In conclusion, in conjunction with psychotherapy, a single moderate-to-high dose of psilocybin was associated with acute and enduring anti-SI and anti-LoM effects in patients with

![Figure 5. Proposed theoretical causal model. Therapeutic effects of psilocybin therapy in the treatment of DHD and SI following a cancer diagnosis. SHT2A: serotonin 2A receptor; CSTC: cortico-striato-thalamo-cortical; DMN: default mode network.](https://doi.org/10.1031/acsptsci.1d00020)
psychiatric and existential distress related to life-threatening cancer. Improvements in other depressive symptoms, as well as in LoM and hopelessness related to demoralization, could represent psychological mechanisms that mediate psilocybin’s effects in reducing SI in patients with cancer. These preliminary results suggest that psilocybin-assisted psychotherapy could be a novel pharmacological–psychosocial treatment modality for advanced-cancer-related suicidality. Further empirical research is needed to definitively establish its efficacy and potential mechanisms of action.

■ ASSOCIATED CONTENT

Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsptsci.1c00020.

Responses to individual suicidal ideation items (PDF)

■ AUTHOR INFORMATION

Corresponding Author
Stephen Ross — NYU Langone Health Center for Psychedelic Medicine, New York 10016, United States; NYU Grossman School of Medicine Department of Psychiatry, New York 10016, United States; Bellevue Hospital Center, New York 10016, United States; orcid.org/0000-0002-7807-3037; Email: stephen.ross@nyulangone.org

Authors
Gabrielle Agin-Liebes — University of California, San Francisco, Department of Psychiatry & Behavioral Sciences, San Francisco, California 94110, United States; Zuckerberg San Francisco General Hospital, San Francisco, California 94110, United States; orcid.org/0000-0002-9754-229X
Sharon Lo — Pacific University College of Health Professions, Hillsboro, Oregon 97123-4218, United States
Richard J. Zeitman — Ryerson University, Toronto, Ontario M5R 2K3, Canada; orcid.org/0000-0003-3478-4483
Leila Ghazal — NYU Langone Health Center for Psychedelic Medicine, New York 10016, United States; NYU Grossman School of Medicine Department of Psychiatry, New York 10016, United States
Julia Benville — NYU Langone Health Center for Psychedelic Medicine, New York 10016, United States; NYU Grossman School of Medicine Department of Psychiatry, New York 10016, United States
Silvia Franco Corso — Columbia University, Department of Psychiatry, New York State Psychiatric Institute, New York 10032-3784, United States
Christian Bjerve Real — Memorial Sloan Kettering Cancer Center, New York 10065-6007, United States
Jeffrey Guss — NYU Langone Health Center for Psychedelic Medicine, New York 10016, United States; NYU Grossman School of Medicine Department of Psychiatry, New York 10016, United States; Bellevue Hospital Center, New York 10016, United States
Anthony Bossis — NYU Langone Health Center for Psychedelic Medicine, New York 10016, United States; NYU Grossman School of Medicine Department of Psychiatry, New York 10016, United States; Bellevue Hospital Center, New York 10016, United States
Sarah E. Mennenga — NYU Langone Health Center for Psychedelic Medicine, New York 10016, United States; NYU Grossman School of Medicine Department of Psychiatry, New York 10016, United States; Bellevue Hospital Center, New York 10016, United States

Grossman School of Medicine Department of Psychiatry, New York 10016, United States

Complete contact information is available at: https://pubs.acs.org/doi/10.1021/acsptsci.1c00020

Funding
The parent study was supported by grants from the Heffter Research Institute, the RiverStyx Foundation, and the New York University-Health and Hospitals Corporation (NYU-HHC) Clinical and Translational Science Institute (CTSI) [NYU CTSA grant UL1TR000038 from the National Center for Advancing Translational Sciences, National Institutes of Health]. Funding for the parent trial was also provided by Carey and Claudia Turnbull, William Linton, Robert Barnhart, Efrem Nulman, Arthur Altschul, Kelly Fitzsimmons, George Goldsmith, and Ekaterina Malievskaia. Funding for G.A.L. was provided by NIH grant T32DA007250.

Notes
The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors acknowledge the contributions of the Center for Psychedelic Medicine Publications Review Committee and Lindsey Owens for their valuable manuscript review.

■ REFERENCES


